Replication-Competent Lentivirus (RCL) Regulatory Compliance Assay (VSV-G/Wild-Type) Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

The development of cell and gene therapies using lentiviral vectors is hindered by stringent regulatory demands for demonstrating the absence of replication-competent lentivirus (RCL), particularly given the inherent risks of insertional mutagenesis and viral spread, alongside the complex matrix effects that can compromise assay sensitivity. Our Replication-Competent Lentivirus (RCL) Regulatory Compliance Assay (VSV-G / Wild-Type) addresses this critical need with a validated, high-sensitivity co-culture system designed to detect both VSV-G-pseudotyped and wild-type RCL. Our service provides end-to-end testing, including sample preparation, amplification, and quantitative endpoint analysis. With broad dynamic range, built-in controls, and rapid turnaround, it offers you robust, audit-ready data to ensure patient safety.

Introduction

Replication-competent lentivirus (RCL) is any lentiviral particle capable of completing a full replication cycle within host cells, arising primarily from homologous recombination between overlapping viral sequences used in vector production systems. The vesicular stomatitis virus G glycoprotein (VSV-G) is the most commonly employed envelope protein for pseudotyping clinical-grade lentiviral vectors, while wild-type envelope variants may occasionally emerge through recombination events or cross-contamination, both of which pose potential safety risks due to their broad tropism and pathogenic capacity.

Fig.1 Cellular host restriction factors act upon lentiviral vectors. (OA Literature) Fig.1 Host cellular factors impose barriers to lentiviral vectors at stages.¹

Our Service

Our RCL assay delivers validated detection of VSV-G and wild-type replication-competent lentivirus, specifically designed for gene therapy product release and regulatory filings. This highly sensitive, quantitative test minimizes false positives while ensuring batch-to-batch consistency. We provide full documentation support, reducing development risks with unparalleled analytical rigor.

What We Can Offer

We offer a comprehensive, regulatory-compliant suite of RCL testing services, combining gold-standard cell-based amplification with advanced molecular platforms to deliver high-sensitivity screening, orthogonal validation, and longitudinal patient monitoring for clinical-grade lentiviral vectors and cell therapies.

Featured services of RCL regulatory compliance assay (VSV-G / Wild-Type) at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Lentiviral Vector Harvest / Finished Product.
CAR-T Cell Product.
Indicator Cells / Amplification Cells.

Key Steps:

Workflow of RCL regulatory compliance assay (VSV-G / Wild-Type) at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Certificate of Analysis.
Raw Data.

Key Advantages

High Sensitivity Through Biological Amplification: We utilize a rigorous 21-day cell passaging regime to exponentially amplify trace viral amounts, achieving an ultra-low limit of detection that minimizes the risk of false negatives.
Replication-Specific Active Virus Differentiation: Our assay specifically detects replication-competent, biologically active lentiviruses rather than inert nucleic acid fragments or plasmid debris, thereby eliminating matrix-induced false positives.
Broad Versatility Across VSV-G Platforms: Our highly permissive indicator cell lines provide superior susceptibility to VSV-G mediated entry, making the assay universally adaptable for both raw viral vectors and diverse cell therapy products like CAR-T.

FAQ

Q1: Why is a 21-day cell amplification assay required instead of direct qPCR for RCL detection?

A1: Direct molecular quantification cannot differentiate infectious viral particles from inert genomic fragments, residual plasmid DNA, or replication-defective vector debris, which frequently leads to false-positive outcomes that compromise product release. To mitigate this risk, global regulatory bodies mandate a three-week co-cultivation phase with highly permissive indicator cells, allowing any scarce, replication-competent contaminants to propagate exponentially and reach detectable thresholds before enzymatic or genetic endpoint analysis.

Q2: What corrective actions should be implemented in the event of a positive RCL result?

A2: A confirmed positive signal necessitates the immediate initiation of a comprehensive deviation investigation, beginning with a thorough laboratory audit to rule out potential cross-contamination from positive control materials, followed by re-testing archival retention aliquots.

Why Choose Us?

With cutting-edge qPCR and cell-culture co-cultivation platforms, we deliver highly sensitive, robust RCL assays compliant with global regulatory standards. Our deep expertise in VSV-G and wild-type lentivirus detection ensures rigorous biosafety validation, accelerating your gene therapy pipelines from discovery to clinical release with unparalleled precision and reliability.

Customer Reviews

"Developing novel lentiviral vectors means we must rigorously exclude any possibility of generating replication-competent recombinants. This service's assay design for detecting wild-type lentivirus and pseudotyped VSV-G remnants is incredibly robust. Their inclusion of stringent positive and negative controls gave our research team complete peace of mind." Prof. J* M*.

"This high-throughput RCL assay service has seamlessly integrated into our workflow. The combination of cell-culture amplification with qPCR readout for VSV-G sequences offered both the cell-based biological relevance and the molecular precision we needed. It significantly reduced our batch testing bottlenecks." E* R*.

How to contact us?

As your partner in RCL safety, we offer expert guidance to streamline your regulatory strategy. Contact our team for a confidential consultation on assay design and validation to accelerate your timeline. We are ready to discuss your specific program needs and provide a customized compliance proposal. Reach out to us today.

Reference

Arduini, Ariana et al. "Progress in Pseudotyping Lentiviral Vectors Towards Cell-Specific Gene Delivery In vivo." Viruses vol. 17,6 802. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/v17060802.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.